Developing Novel Solutions for ADPKD: An Interview with XORTX Therapeutics’ CEO Dr. Allen Davidoff
There are limited therapeutic options for people living with autosomal dominant polycystic kidney disease (ADPKD); currently, the only real standards-of-care include dialysis and kidney transplantation. When discussing the therapeutic landscape,…